Clinical Trials Logo

Parkinson Disease, Secondary clinical trials

View clinical trials related to Parkinson Disease, Secondary.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT05607862 Active, not recruiting - Parkinson Disease Clinical Trials

Home Physiotherapy in Frailty in Patients With Parkinson's Disease or Secondary Parkinsonism

Start date: October 15, 2022
Phase: N/A
Study type: Interventional

The aim of this protocol is to evaluate the effects of a home-based therapeutic exercise program applied in patients with PD or secondary parkinsonism to reverse frailty. The design of this study is experimental, prospective, randomized and single blind. The study population that will be part of this study will be men and women with a diagnosis of PD or secondary parkinsonism belonging to the Health Area V of the Health Service of the Principality of Asturias, Spain.

NCT ID: NCT05273957 Active, not recruiting - Parkinson Disease Clinical Trials

A Model of Hospital-Territory Management Coordinated by a Case Manager to Improve the Care of Patients With Parkinsonism.

PROUD
Start date: March 29, 2021
Phase: N/A
Study type: Interventional

The present multicenter randomized study investigates whether the management of patients with parkinsonism by a nurse specialist (case-manager) can significantly improve patients' quality of life over 12 months, compared to control patients managed with the standard-of-care process. Participants will be evaluated with clinical scales testing quality of life, motor and non-motor symptoms, and the number of unscheduled hospital access throughout the course of the study.

NCT ID: NCT02598973 Active, not recruiting - Parkinson's Disease Clinical Trials

Effect of Exercise in Parkinsonism

Start date: February 1, 2016
Phase: Phase 1/Phase 2
Study type: Interventional

Parkinson's disease (PD) is a common neurodegenerative disorder affecting approximately 80,000 Veterans, representing a priority area for VA research. Current medicines for PD only improve symptoms, treatments that slow disease progression are needed, and earlier diagnosis of PD may be the key to their development. PD symptoms can be mimicked by medicines (most commonly antipsychotic drugs that block dopamine), and some of these patients actually have underlying "prodromal" PD that was "unmasked" years before it would have caused symptoms. This problem is increasing as these medicines are now used for common conditions including post-traumatic stress disorder and depression. The investigators will identify prodromal PD in patients with drug-induced symptoms using brain scans. These patients will be enrolled in a randomized clinical trial of aerobic exercise which slows progression in animal models of PD and has other health benefits. The investigators will measure the effect of exercise on symptoms, disease progression (using brain scans) and markers of PD risk (using blood tests). These studies will improve early PD diagnosis and potentially identify a way to slow progression of PD.